Skip to main content
. 2020 Sep 25;12(10):2758. doi: 10.3390/cancers12102758

Figure 2.

Figure 2

ITPKC gene expressions and clinical features including survival in the TCGA and GSE5066 breast cancer cohort. (A) Boxplots of the ITPKC expression by American Joint Committee on Cancer (AJCC) stage, Nottingham pathological grade and breast cancer subtype. One-way ANOVA test was used to calculate p values. Tukey-type boxplots show median and inter-quartile level values. (B) Association between ITPKC expression and survival of breast cancer patients in the TCGA and GSE25066 cohorts. Overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) of ITPKC expression low and high in whole breast cancer cohort (Whole), estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), triple negative breast cancer (TNBC) and HER2+ in the TCGA cohort and DFS in the GSE25066 cohort. The top quartile was defined as the high-score group within each cohort. Log rank test was used to compare between two groups with Kaplan–Meier survival curves and to calculate p values.